Enzyme Or Coenzyme Containing Patents (Class 424/94.1)
  • Patent number: 11065294
    Abstract: Provided is a composition for enhancing effects of an anticancer agent using an oriental medicine, jaeumganghwa-tang, bojungikgi-tang, or yukmijihwang-tang. More particularly, provided is a composition for treating a neoplastic disease by administering an anticancer agent into an individual, and administering an oriental medicine into the individual within 30 minutes. The composition remarkably reduces side effects occurring when the anticancer agent is administered alone by co-administration of the oriental medicine, reduces cytotoxicity, and has higher anticancer activity than that when the anticancer agent is administered alone.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: July 20, 2021
    Assignee: COMPREHENSIVE AND INTEGRATIVE MEDICINE INSTITUTE
    Inventors: Joon Seok Byun, Sae Kwang Ku, Ki Cheul Sohn, Seung Mo Kim, Chang Hyeong Lee, Dae Sung Hyun, Jong Dae Kim, Sung Hwan Park, Min A. Kwak
  • Patent number: 11053271
    Abstract: The disclosure provides methods and compositions for the integration (insertion) of a donor DNA molecule into a target DNA molecule. In general, the methods include contacting a target DNA molecule with a linear donor DNA molecule and a Cas 1 protein, where the target DNA molecule includes an AT-rich region (e.g., in some cases positioned 5 and within 50 nucleotides of a region that forms a DNA cruciform structure), where the contacting is not in a bacterial or archaeal cell (e.g., the contacting is in vitro outside of a cell, inside of a eukaryotic cell, etc.), and provides for integration of the donor DNA molecule into the target DNA molecule.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: July 6, 2021
    Assignee: The Regents of the University of California
    Inventors: James K. Nunez, Jennifer A. Doudna
  • Patent number: 11049591
    Abstract: A system and method is disclosed that establishes communication between a host system and a user device. The host system automatically registers individualized diet data received from the user device. The individualized diet data has parameters indicative of type and quantity of foods or supplements consumed by a user during a defined time period. The parameters are analyzed with a predetermined rule set indicative of concentrations of DHA in select foods and supplements to determine a level of the user's DHA dietary intake relative to a recommended intake. An alert is generated by the host system and transmitted via at least one predetermined communication method and without user intervention, responsive to the user's dietary intake relative to the recommended intake being a predetermined relation to a baseline.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: June 29, 2021
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Manxi Bai, Jie Huang
  • Patent number: 11041173
    Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: June 22, 2021
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng Zhang, Randall Jeffrey Platt, Guoping Feng, Yang Zhou
  • Patent number: 11033575
    Abstract: The present invention relates to the treatment of refractory Emotional Cognitive Disconnect (ECD) through a combination of pharmaceutical agents and therapy. Individual patients are treated with a combination of magnesium, inositol, and N-acetylcysteine along with Vitamin E, Vitamin C, zinc, biotin, alphalipoic acid and lysine as required. The compositions may be administered sequentially or simultaneously in any order and may be formulated in singular or combinatorial dosage forms.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: June 15, 2021
    Inventor: Jeanne Fleming
  • Patent number: 11016104
    Abstract: A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: May 25, 2021
    Assignee: CUREMARK, LLC
    Inventor: Joan M. Fallon
  • Patent number: 11008554
    Abstract: Disclosed herein are methods for the large-scale production of a highly thermally stable acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Additionally, the expression methods disclosed herein can produce ChE preparations consisting of extract or purified forms that can be produced in high amounts and are highly thermally stable. These ChE products can be used in vitro detection, detoxification and decontamination methods.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: May 18, 2021
    Assignee: PlantVax, Inc.
    Inventor: Yvonne J. Rosenberg
  • Patent number: 11001844
    Abstract: CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: May 11, 2021
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot
  • Patent number: 10973859
    Abstract: Compositions include arginine and one or more unsaturated fatty acids. Methods for using such compositions can enhance cognitive function, reduce or prevent a decline of social interaction, reduce or prevent age-related behavioral changes, increase trainability, maintain optimal brain function, facilitate learning and memory, reduce memory loss, retard brain aging, prevent or treat strokes, and/or prevent or treat dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: April 13, 2021
    Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S. A.
    Inventor: Yuanlong Pan
  • Patent number: 10946108
    Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: March 16, 2021
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HAVARD COLLEGE
    Inventors: Feng Zhang, Le Cong, Fei Ran, Matthias Heidenreich, Lukasz Swiech
  • Patent number: 10925934
    Abstract: A spray dried myrosinase/ascorbate mixture is formed from the steps comprising: providing a source of myrosinase, adding ascorbate to the source of myrosinase, heating the source of myrosinase to a temperature of about 104° F. (about 40° C.) or higher, and spray drying the myrosinase/ascorbate mixture. The spray dried myrosinase/ascorbate mixture may be used to prepare isothiocyanates. The spray dried myrosinase/ascorbate mixture may also be mixed with glucoraphanin and used in an activated tablet or capsule.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: February 23, 2021
    Assignee: Caudill Seed and Warehouse Co., Inc.
    Inventors: Richard C. Sullivan, Joseph A. Lyons, Sanford D. Caudill
  • Patent number: 10898525
    Abstract: A preparation comprising krill oil and phospholipids. Methods of treatment comprising administering the same.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: January 26, 2021
    Assignee: AKER BIOMARINE ANTARCTIC AS
    Inventors: Sigalit Zchut, Itay Shafat, Inbal Eyal, Gai Ben-Dror, Hala Laoz, Ofer Bonen
  • Patent number: 10894062
    Abstract: The embodiments relate to improved vitamin supplement compositions formulated for administration to patients, particularly improved vitamin compositions formulated for use in cosmetic or therapeutic applications. The compositions may be used to slow aging process and promote wellness including treating a vitamin deficiency, skin conditions, improving skin appearance, wound healing and scar prevention and hair loss.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: January 19, 2021
    Assignee: AQUAVIT PHARMACEUTICALS, INC.
    Inventor: Sobin Chang
  • Patent number: 10869955
    Abstract: The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: December 22, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Guang-Liang Jiang, Catherine C. Turkel, Michael E. Stern, Christopher S. Schaumberg, Wendy M. Blanda
  • Patent number: 10849878
    Abstract: The agent with antistress, anxiolytic and antidepressant activity and a composition based on it. The invention relates to the field of pharmaceutics, particularly to chemical compounds based on lithium salts, namely to substances with antistress, anxiolytic and antidepressant activity and can be used in medicine, veterinary medicine, and the pharmaceutical industry. The invention discovers the possibility of using lithium ascorbate as an agent with antistress, anxiolytic and antidepressant activity. The claimed composition with antistress, anxiolytic and antidepressant activity, including a lithium salt, contains pyridoxine hydrochloride, thiamine mononitrate and lithium ascorbate as a lithium salt. The use of lithium ascorbate as an agent with antistress, anxiolytic and antidepressant action and the composition based on it, enables to expand the assortment of the agents for indicated administration. At the same time, the claimed agents have low toxicity and high efficacy.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: December 1, 2020
    Assignee: OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU “NORMOFARM”
    Inventors: Viacheslav Valerievich Rastashanskiy, Konstantin Sergeevich Ostrenko
  • Patent number: 10822606
    Abstract: Methods, compositions, and kits are provided herein for CRISPER/Cas-mediated nucleic acid detection or modification.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: November 3, 2020
    Assignee: The Regents of the University of California
    Inventors: Bo Huang, Baohui Chen, Lei Qi, Luke Gilbert
  • Patent number: 10813984
    Abstract: The present invention provides a peptide-based immunotherapy for ASPH-expressing tumors.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: October 27, 2020
    Assignee: Rhode Island Hospital
    Inventor: Jack R. Wands
  • Patent number: 10781444
    Abstract: The present invention generally relates to libraries, compositions, methods, applications, kits and screens used in functional genomics that focus on gene function in a cell and that may use vector systems and other aspects related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas systems and components thereof. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: September 22, 2020
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng Zhang, Ophir Shalem, Neville Espi Sanjana, John Doench, David Root, Ella Nicole Biewener Hartenian
  • Patent number: 10765641
    Abstract: The present invention relates to the novel combination of pongamia oil and 4-t-butylcyclohexanol, and to the uses thereof in the fields of cosmetics and dermatology to combat redness. More specifically, the present invention relates to the cosmetic use of a composition comprising said combination to combat rosacea.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: September 8, 2020
    Assignee: PIERRE FABRE DERMOT-COSMETIQUE
    Inventors: Hélène Hernandez-Pigeon, Nathalie Castex-Rizzi, Stéphane Poigny, Marie Françoise Aries, Yves Brunel
  • Patent number: 10717990
    Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: July 21, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Prashant G. Mali, George M. Church, Luhan Yang
  • Patent number: 10711259
    Abstract: Compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity for use in e.g. animal feed. Polypeptides having arabinofuranosidase activity, polypeptides having xylanase activity and polynucleotides encoding the polypeptides. Nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptide.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 14, 2020
    Assignee: Novozymes A/S
    Inventors: Wei Peng, Ninfa Rangel Pedersen, Dan Pettersson, Jens Magnus Ekloff, Soren Nymand-Grarup, Lorena G. Palmen, Rune Nygaard Monrad, Nikolaj Spodsberg, Mary Ann Stringer, Charlotte Blom, Lars Kiemer, Kristian Bertel Romer M. Krogh, Jesper Salomon
  • Patent number: 10704098
    Abstract: Compositions and methods for the treatment and diagnosis of eosinophilic esophagitis disclosed.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 7, 2020
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Hakon Hakonarson, Patrick Sleiman
  • Patent number: 10695320
    Abstract: The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: June 30, 2020
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher Rinsch, William Blanco-Bose
  • Patent number: 10655123
    Abstract: The invention provides a method of modifying a targeted site of a double stranded DNA, including a step of contacting a complex wherein a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in a selected double stranded DNA and a nucleic acid base converting enzyme are linked, with the double stranded DNA, to convert one or more nucleotides in the targeted site to other one or more nucleotides or delete one or more nucleotides, or insert one or more nucleotides into the targeted site, without cleaving at least one strand of the double stranded DNA in the targeted site.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: May 19, 2020
    Assignee: National University Corporation Kobe University
    Inventors: Keiji Nishida, Akihiko Kondo, Satomi Kojima
  • Patent number: 10568866
    Abstract: A composition of natural and chemical nutrients such as Vitamin C, Vitamin B-complex, Vitamin E, Aronia melanocarpa extract, Fucoidan, Ginger extract, Zinc, Selenium, Alpha lipoic acid, White mulberry extract, Lychee fruit extract and Sour (Tart) cherry fruit extract are made for mammal consumption in liquid or solid form. This specific composition is used for increasing innate immunity in the mammal before and after the infection has occurred.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: February 25, 2020
    Inventor: Matthias W Rath
  • Patent number: 10568843
    Abstract: The present invention provides a method of preparing highly stable microcapsule powders or microparticles containing a fat-soluble nutrient having multiple double bonds.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: February 25, 2020
    Assignee: Zhejiang Medicine Co., Ltd
    Inventors: Xinde Xu, Di Zhou, Lihua Zhang, Bin Shao
  • Patent number: 10519504
    Abstract: Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: December 31, 2019
    Assignee: Berg LLC
    Inventors: Niven Rajin Narain, John Patrick McCook, Rangaprasad Sarangarajan
  • Patent number: 10519324
    Abstract: Materials and methods for prevention of biofouling are described that incorporate the presence of a conotoxin peptide on a surface. The conotoxin peptide is either directly or indirectly adhered to the surface and interferes with the ability of biofouling organisms to settle on the surface.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: December 31, 2019
    Assignee: Clemson University Research Foundation
    Inventors: Andrew S. Mount, Bin San Chan, Mary Beth Johnstone
  • Patent number: 10501557
    Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52 wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: December 10, 2019
    Assignee: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Gustav Rodrigo, Tomas Bjorkman, Mats Ander
  • Patent number: 10494417
    Abstract: In one aspect, the invention relates to peptides comprising the Bcr-Abl coiled-coil oligomerization domain and an alpha helix stabilizing moiety, mutant forms thereof, truncated forms thereof, derivatives thereof, and related peptides, which are useful as inhibitors of the Bcr-Abl chimeric protein; pharmaceutical compositions comprising the compounds; and methods of treating hyperproliferative disorders associated with Bcr-Abl using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: December 3, 2019
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Carol Lim, Benjamin J. Bruno, Geoffrey D. Miller, Andrew S. Dixon
  • Patent number: 10485836
    Abstract: A composition and its use in anti-fatigue are provided, wherein the composition comprises a first component being a Cistanche tubulosa extract and a second component being ubiquinone (Q10) and/or ubiquinol (QH), and the weight ratio of the first component to the second component ranges from 0.67:1 to 10:1. The composition is used for anti-fatigue and is a pharmaceutical composition, a food composition, a cosmetic composition, a care product composition, or a feed composition. The pharmaceutical composition is used for treating or preventing chronic fatigue syndrome, and the food composition, the cosmetic composition, the care product composition and the feed composition are used for at least one of increasing endurance performance, increasing athletic ability, increasing physical strength, recovering physical strength, promoting fatigue elimination, preventing myocardial weakness, helping ameliorate myocardial weakness and helping improve cardiac function.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: November 26, 2019
    Assignee: SINPHAR PHARMACEUTICAL CO., LTD.
    Inventors: Wen-Pang Huang, Ya-Ting Wu
  • Patent number: 10478447
    Abstract: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 19, 2019
    Assignee: Vymedic, LLC
    Inventors: Kenneth E. Phillips, Cynthia A. Winning
  • Patent number: 10413563
    Abstract: A novel process for improving neurochemical health includes a multi-day treatment program including intravenous delivery of nicotinamide adenine dinucleotide (NAD) to at least partially restore a patient's brain to a desired chemical balance. Intravenous delivery of NAD is synergistically combined with delivery of selected amino acids and, depending on the ailment being treated, a combination of ozone, testosterone, glutathione, Myers cocktail or other specified compounds.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: September 17, 2019
    Assignee: Emerald Neuro-Recover, LLC
    Inventor: Joseph W. Pappas
  • Patent number: 10406104
    Abstract: The present application relates to a method for the preparation of a nanosuspension comprising nanoparticles of at least one natural material and an extract of at least one natural material, wherein the method comprises the steps of providing particles of at least one natural material having a particle size (D100) of less than 320 ?m; providing an extract of at least one natural material; dispersing said particles of at least one natural material and said extract of at least one natural material in a solvent; and milling the dispersion to a particle size (D90) of below 1000 nm (D90<1000 nm). Furthermore, the present application also relates to a nanosuspension prepared according to said method, and the use of such nanosuspension for the preparation of a medicament and/or nutritional supplement.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: September 10, 2019
    Assignee: Apurano Life Sciences GmbH
    Inventor: Werner Brand
  • Patent number: 10357547
    Abstract: The invention relates to the field of medicine, specifically to the field of treatment of dermatitis or eczema, even more specifically to the field of treatment of atopic dermatitis. The invention relates to a novel composition and a novel kit of parts, both comprising an anti-inflammatory compound and a compound specifically targeting a bacterial cell, preferably a gram positive bacterial cell. The invention further relates to said composition and/or kit of parts for medical use, preferably for treating an individual suffering from eczema.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: July 23, 2019
    Assignee: Micreos Human Health B.V.
    Inventors: Mark Leonard Offerhaus, Fritz Eichenseher, Martin Johannes Loessner
  • Patent number: 10328152
    Abstract: A method of treatment is disclosed, comprising administering a composition of Cyclodextrin and reduced, nanonized L-Glutathione to a patient in need of treatment, wherein the L-Glutathione molecule is non-acetylated, non-Esterified, and non-fatty acid attached.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: June 25, 2019
    Inventors: Nayan Patel, Chinh Tran
  • Patent number: 10328090
    Abstract: Described herein are formulations and methods for treating, managing, or preventing sleeplessness or restlessness, for increasing focus or concentration, or for decreasing anxiety. The formulations comprise honokiol and magnolol, which are present in magnolia bark extract, in admixture with one or more polyunsaturated fatty acids, such as those found in virgin salmon oil. As compared to other lipid formulations of honokiol and magnolol, the formulations show improved stability and increased uptake.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: June 25, 2019
    Assignee: ST IP Holding AG
    Inventor: Bomi P. Framroze
  • Patent number: 10322170
    Abstract: The invention discloses a hemostatic composition comprising: a) a biocompatible polymer in particulate form suitable for use in hemostasis, and b) one hydrophilic polymeric component comprising reactive groups.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 18, 2019
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Heinz Gulle, Joris Hoefinghoff, Andreas Goessl, Katarzyna Gorna
  • Patent number: 10278909
    Abstract: The present invention relates to a composition for pharmaceutical, nutritional or cosmetic use, suitable to preserve the physiological condition and health of skin and hair and to reestablish their regenerative functions, characterized in that it comprises a mixture of carnitine, caffeine and arginine as active principle, as such or as derivatives, such as pharmacologically acceptable salts. The effect of preserving the physiologic condition and health of skin and hair, and of reestablishing their regenerative functions is mainly achieved through an increase in ATP production by skin and hair cells.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 7, 2019
    Assignee: Giuliani S.P.A.
    Inventors: Giammaria Giuliani, Anna Benedusi, Barbara Marzani, Antonio Mascolo, Antonio Limitone
  • Patent number: 10284587
    Abstract: The disclosed computer-implemented method for responding to electronic security incidents may include (i) identifying a plurality of security incidents that each occurred within a computing environment and call for a security response, (ii) establishing relationships among the plurality of security incidents by, for each security incident, (a) calculating a feature vector indicating at least one feature of the security incident, (b) using the feature vector to calculate a degree of similarity between the security incident and an additional security and (c) creating an association between the security incident and the additional security incident that reflects the degree of similarity between the security incident and the additional security incident, and (iii) triggering, based on the relationships among the plurality of security incidents, a security action that responds to at least the security incident and the additional security incident.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: May 7, 2019
    Assignee: Symantec Corporation
    Inventors: Brian Schlatter, Adam Glick, Akshata Krishnamoorthy Rao, Feng Li
  • Patent number: 10273296
    Abstract: Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-? antagonist. TNF-? antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: April 30, 2019
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Jagdeep Nanchahal, Kim Suzanne Midwood
  • Patent number: 10258073
    Abstract: The present invention discloses a functional nutritional blend comprising Gynostemma pentaphyllum extract, Coleus forskohlii extract, Zingiber officinale extract and piperine, for increasing metabolic efficiency and inhibition of adipogenesis.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: April 16, 2019
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Mitchell Chavez
  • Patent number: 10245304
    Abstract: The invention provides methods of treating ?-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human ?-galactosidase A are also included.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: April 2, 2019
    Assignee: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Douglas A. Treco, Kenneth Loveday, Marianne Borowski
  • Patent number: 10246497
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: April 2, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
  • Patent number: 10239832
    Abstract: Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: March 26, 2019
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventor: Bing Wang
  • Patent number: 10238617
    Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: March 26, 2019
    Assignee: AXCELLA HEALTH INC.
    Inventors: Michael Hamill, Raffi Afeyan, Chung-Wei Lee, Harry Luithardt, David Berry
  • Patent number: 10203323
    Abstract: Disclosed herein are methods for identifying novel drug candidates.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: February 12, 2019
    Assignee: Warp Drive Bio, Inc.
    Inventors: Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
  • Patent number: 10201513
    Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: February 12, 2019
    Assignee: AXCELLA HEALTH INC.
    Inventors: Michael Hamill, Raffi Afeyan
  • Patent number: 10172820
    Abstract: The present invention relates to a skin preparation composition for external use having excellent antiseptic ability without using chemical antiseptics. More particularly, the present invention relates to a skin preparation composition for external use, comprising: glyceryl undecylenate having excellent antiseptic ability; and one or more mixtures of ethylhexylglycerin, glyceryl caprylate, p-anisic acid and a citrus mixed extract, thus improving antiseptic ability through the increased effects of antiseptic abilities of those materials.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: January 8, 2019
    Assignee: Amorepacific Corporation
    Inventors: Il Young Kwack, Yu Na Yun, Tae Hun Park, Jin Sol Kim, Yun Hyeok Jung, Yeon Ju Hong, Kye Ho Shin
  • Patent number: 10154977
    Abstract: Described herein are compositions and methods relating to particles comprising at least one component of a cellular-derived microparticle. Aspects of technology described herein relate to compositions and methods for treating inflammation, wounds, and pain.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: December 18, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. Serhan, Lucy V. Norling, Matthew Spite, Jesmond P. Dalli